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Cathepsin LAdvanced glycation end-products (AGEs) comprise a group of non-enzymatic post-translationalmodiﬁcations of
proteins and are elevated in diabetic tissues. AGE-modiﬁcation impairs the digestibility of collagen in vitro but
little is known about its relation to collagen-degrading proteinases in vivo. Nε-carboxymethyllysine (CML) is a
stable AGE that forms on lysyl side-chains in the presence of glucose, probably via a transition metal-catalysed
mechanism.
Here, rats with streptozotocin-induced diabetes and non-diabetic controlswere treated for 8weekswith placebo
or the Cu(II)-selective chelator, triethylenetetramine (TETA), commencing 8 weeks after disease induction.
Actions of diabetes anddrug treatmentweremeasured on collagen and collagen-degrading proteinases in kidney
tissue.
The digestibility and CML content of collagen, and corresponding levels of mRNAs and collagen, were related to
changes in collagen-degrading-proteinases. Collagen-degrading proteinases, cathepsin L (CTSL) and matrix
metalloproteinase-2 (MMP-2) were increased in diabetic rats. CTSL-levels correlated strongly and positively
with increased collagen-CML levels and inversely with decreased collagen digestibility in diabetes. The
collagen-rich mesangium displayed a strong increase of CTSL in diabetes. TETA treatment normalised kidney
collagen content and partially normalised levels of CML and CTSL.
These data provide evidence for an adaptive proteinase response in diabetic kidneys, affected by excessive
collagen-CML formation and decreased collagen digestibility. The normalisation of collagen and partial normal-
isation of CML- and CTSL-levels by TETA treatment supports the involvement of Cu(II) in CML formation and
altered collagen metabolism in diabetic kidneys. Cu(II)-chelation by TETA may represent a treatment option to
rectify collagen metabolism in diabetes independent of alterations in blood glucose levels.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
CML is a major AGE that is said to form via the ‘glycoxidation path-
way’ (also known as ‘autoxidative glycation’), which involves the
reaction of glucose with proteins, catalysed by transition metals such
as copper [1,2]. The AGE formation is enhanced in diabetes [3] where
it has been linked to decreased collagen digestibility [4,5] and altered
proteolytic processing of albumin in vitro [6].s, Faculty of Science, University
and.
r).The capacity of the proteolytic system may eventually become
exhausted by excessive AGE formation and AGE accumulation in lyso-
somes has been demonstrated in vitro [7]. Consequently, proteinases in-
volved in the degradation of collagen could be affected by altered AGE
content of substrate proteins in diabetes, but data concerning in vivo
collagen-AGE formation that pertain to roles of collagen-degrading
proteinases are lacking. Distinguishing between substrates modiﬁed
with AGEs in vitro compared with in vivo is recognised as an important
question, and has generated discussion regarding the interaction of
AGE-modiﬁed proteins with the receptor for AGEs (RAGE) [8].
MMP-2 and certain cathepsins are implicated in soft-tissue collagen
turnover [9,10]. Previous reports regarding collagen degradation in dia-
betic kidneys are contradictory. Increased proteolytic activity towards
Table 1
Primer sequences for RT qPCR.
List of primers
Gene abbreviation Forward primer sequence Reverse primer sequence
Col1a1 ACATGTTCAGCTTTGTGGACC TTAGGGACCCTTAGGCCATT
Col1a2 AGAAAATGGCATCGTTGGTC ACCAGGGAAGCCAGTCATAC
Col3a1 TATTTTGGCACAGCAGTCCA CAGAGGACAGATCCCGAGTC
Col4a1 GTCCTCACTGTGGATTGGCT CGATGAATGGGGCACTTCTA
Col4a4 CAGATGGACCGAGTCCTACG TCTTGCTGCTCCCATATTCA
Col4a5 GATCTCCAGGTGACCAAGGA CCTGAAATGCCAGTTCCAAT
Col6a1 GCTGAGCAAGGACGAGCTAG CACGTGTTCTTGCATCTGGT
Col6a2 GACTTTGGTCTGAAAGGAGCA GGGTTCTCCCTCAGGTCCT
Col6a3 TACCGAGCATCTGAGGAGCT GAACTCCACTTGCATCAGCC
Ctsl AAGCCCTCATGAAGCCTGTAG CCTTGCTGCTACAGTTGGGTT
Lox CTGACTTCTTACCAAGCCGC GCAGGTCGTAGTGGCTGAAT
Mmp2 CTTTGATGGCATTGCTCAGA GTCACGTGGTGTCACTGTCC
Rpl13a ACAAGAAAAAGCGGATGGTG TTCCGGTAATGGATCTTTGC
Tbp AGAACAATCCAGACTAGCAGCA GGGAACTTCACATCACAGCTC
U2af CCATTGCCCTCTTGAACATT CCTCCCCGTACTTCTCTTCC
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ular homogenates from ratswith streptozotocin (STZ)-induced diabetes
after 4 and 10 weeks' hyperglycaemia [11]. This ﬁnding contrasts with
data obtained using artiﬁcial substrates for collagen-degrading cathep-
sins as well as gelatine zymography for metalloproteinases, whereby
decreased activity was reported in glomeruli of STZ-diabetic rats with
up to 5-weeks' diabetes [12]. Activity of CTSL was reportedly decreased
in kidneys of STZ-diabetic rats 10 and 30 days after disease induction
[13] while activity was decreased and unchanged after 10 days and 6-
months in proximal-tubular cells, respectively [14].
The aim of this study was to investigate the relation between modi-
ﬁcations of collagen and collagen-degrading proteinases in healthy and
STZ-diabetic rats. The Cu(II) chelator TETA, was previously shown to
prevent albuminuria and heart failure in diabetic rats [15,16], and was
here investigated as an interventional treatment against AGE formation
and linked effects on collagen homeostasis.
2. Materials and methods
2.1. Animal studies
All protocols were approved by the University of Auckland Animal
Ethics Committee and complied with the ‘Principles of Laboratory Ani-
mal Care’ (NIH 1985): this report is consistent with current guidelines
for the proper reporting of animal experiments [17]. Male Wistar rats
8 weeks of age with body-weights of 300 g (±30 g) (mean ± SEM)
were injected once via the tail vein with a solution of saline vehicle or
STZ (S0130, Lot No. 119K1591, Sigma-Aldrich, USA; 55.0 mg/kg body-
weight) in saline solution. Rats were fed chow (Teklad Diet No. 2018;
Harlan Laboratories, USA) and water ad libitum. Thereafter, body-
weights of animals were measured weekly and non-fasting blood-
glucose levels fortnightly. Treatment of rats with placebo (water) or
TETA dihydrochloride (~17 mg/day; T5033, Sigma-Aldrich, USA) was
started 8 weeks after injection in one-half of the STZ- and saline-
injected animals, andwas administered via the drinkingwater as previ-
ously described [15]. Kidneys were perfused and collected at the end of
experimental week 16, following 8-weeks' drug treatment. RNAlater
(AM7021, Life Technologies, USA)was added to those samples destined
for RNA analysis and samples were stored at−80 °C. Light microscopy
of haematoxylin-and-eosin-stained renal-cortical sections was per-
formed, and showed that rats had not developed renal tumours, consis-
tent with a lack of renal STZ toxicity.
2.2. Gene expression analysis
RNA was extracted from renal cortical tissue using spin columns
(QIAGEN, Germany). Complementary DNA synthesised using the
Transcriptor cDNA kit with an oligo-dT primer (Roche, Germany) and
subsequently analysed using the Light Cycler 480 system and SYBR
green MasterMix (both Roche). Target gene levels were normalised to
three reference genes, which were stably and similarly expressed in
all four groups of animals. All primers (Table 1) were designed to be
intron-spanning.
2.3. Western blotting
Protein levels of lysyl oxidase (LOX) (sc-32410; Santa Cruz, USA)
and CTSL (ab6314; Abcam, UK) in kidney-cortex lysates were detected
byWestern blotting as described [16], and normalised to corresponding
beta-actin values (sc-47778; Santa Cruz).
2.4. Gelatinase activity assay
Tissue samples were lysed (10 mM CaCl2, 0.25% v/v Triton-X100)
and run on gelatine-containing polyacrylamide gels (EC 61752, Life
Technologies, USA). These were equilibrated at RT for 30 min inrenaturation buffer (LC2670, Life Technologies), and then incubated in
developing buffer (LC2671, Life Technologies) for 30 min at RT. Buffer
was then refreshed, and gels incubated for 72 h at 37 °C. Gels were
stained with Coomassie blue [18]. EDTA (10 mM) was added as a nega-
tive control to the ﬁrst incubations on a separate control gel to conﬁrm
that the activity was metalloproteinase-dependent.
2.5. CTSL activity assay
CTSL activity was assayed using a peptide substrate, Ac-HRYR-ACC
(Cat # 219497; Merck, Germany), coupled to the probe, ACC (7-
amino-4-carbamoylmethylcoumarin), which ﬂuoresces following
cleavage. The assay was performed as described by Choe et al. [19]
with minor modiﬁcations. In brief, renal cortex was lysed (30 mM
Tris–HCl, 0.1% Brij-35 v/v, 1 mM DTT) and mixtures centrifuged
(15 min, 16,100 g, 4 °C). Supernatants were collected on ice, and 10 μL
(~30 μg) of each was added in triplicate to a black 96-well plate. The
activity-assay buffer (100 mM sodium acetate, 100 mM NaCl, 1 mM
EDTA, 0.01% Brij-35 (v/v), DTT 10 mM, pH 5.5 with substrate/DMSO to
5 μM) was pre-warmed to 30 °C, and added alongside a standard
curve. Fluorescence was measured (excitation, 380 nm; emission,
460 nm; cut-off, 435 nm) after 10 min incubation at 30 °C. Activity
was normalised for protein concentration as determined by BCA assay.
TETA (25 μM) and/or CuCl2 (25 μM) were added for relative CTSL
activity assay, and comparisons made to wells containing the lysate
without either of these compounds (100% activity).
2.6. Collagen extraction
Collagen was extracted from kidney tissues after removal of the
renal pelvis and major calyces, and puriﬁed according to a published
protocol [20].
2.7. Quantiﬁcation of collagen levels
Collagen was quantitated by measurement of hydroxyproline levels
in acid hydrolysates (6 M HCl at 105 °C for 16 h) of the kidney or colla-
gen extracts according to the procedure of Bergman and Loxley [21].
2.8. Determination of collagen pepsin digestibility
Collagen extracts were digested with 1 mg/ml pepsin/0.5 M acetic
acid at a concentration of 1 mg/ml for 24 h at 4 °C. Digests were then
centrifuged (16,100 g, 4 °C, 30 min). Hydroxyproline levels in superna-
tants and pellets were measured, and the digestibility presented as the
percentage of total collagen.
Fig. 1. Average blood-glucose levels (A) and body-weights (B) of the four groups over 16 weeks are shown. Commencement of placebo or TETA treatment is as indicated (black arrow).
Symbols are: white squares, Sham/Plac; black squares, Sham/TETA; white triangles, Dia/Plac; black triangles, Dia/TETA: n= 11/12 per group; and *, P b 0.05 vs. Sham/Plac. Nonstandard
abbreviations: Dia, diabetic; Plac, placebo-treated; and TETA, triethylenetetramine-treated.
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Collagen extractswere solubilised by digestionwith pepsin and sep-
arated by SDS-PAGE, stainedwith Coomassie blue [18]. Individual bands
were de-stained and proteins identiﬁed using a QSTAR-XL Quadrupole
Time-of-Flight mass spectrometer (Applied Biosystems, USA) following
in-gel trypsin digestion.
2.10. Quantiﬁcation of CML levels
CML levels were measured in kidney collagen extracts solubilised
with Liberase DH (Roche, Germany). Equal amounts of collagen, as de-
termined by hydroxyproline measurement, were loaded in triplicate
onto a nitrocellulose membrane. An AGE standard (produced by incu-
bating BSA with fructose/PBS for 8 weeks followed by dialysis) was
loaded onto each blot for purposes of normalisation. CML levels were
detected using a monoclonal antibody (KAL-KH024, Cosmo Bio, Japan)
followed by an HRP-conjugated secondary antibody and ECL detection,Fig. 2. Annotated collagen isoforms on Coomassie blue-stained SDS-PAGE (A) were identiﬁed
Molecular weight marker [kD] is indicated. A representative blot for the quantiﬁcation of co
shown for each sample. Speciﬁcity of the signal was conﬁrmed in (C) by incubation of the mo
of CML levels (D) and pepsin digestibility (E) of kidney collagen extracts of the four group
per group: *, P b 0.05 vs. Sham/Plac; †, P b 0.05 vs. Dia/Plac. Nonstandard abbreviations: AGE, a
Nε-carboxymethyllysine; Dia, diabetic; LC, liquid chromatography; MS, mass spectrometry; anafter which ECL signals were quantitated by densitometry. Speciﬁcity of
the antibody was conﬁrmed by treatment with the CML-blocking
peptide (YAAA(CML)AAA), which was synthesised in-house as de-
scribed previously [22].
2.11. Immunoﬂuorescent staining
Staining was performed as described previously [23] with minor
modiﬁcations. In short, frozen sections were acetone-ﬁxed and
stained using primary antibodies against CTSL (ab6314, Abcam,
UK) and type 1 collagen (ab34719, Abcam, UK), and Alexa 647-
(A21240, Life Technologies, USA) and Alexa 488-coupled (A11034,
Life Technologies, USA) secondary antibodies, respectively. Sections
were treated with Sudan Black B (199664, Sigma-Aldrich, USA)
[24] prior to ﬁxation and DAPI counterstaining (P36941, Life Tech-
nologies, USA). Sections were analysed using a ﬂuorescence micro-
scope (Leica DMR, Leica, Germany) and camera (Spot pursuit, Spot
Imaging Solutions, USA).by LC MS/MS analysis or by comparison to the available literature (shown in parentheses).
llagen-bound CML including a BSA-AGE standard curve is shown in (B) with triplicates
noclonal antibody with (+BP) or without a CML-blocking peptide (-BP). Quantiﬁcation
s are shown alongside collagen levels in kidney cortices (F) of the groups: n = 11/12
dvanced glycation end-product; Bp, blocking peptide; BSA, bovine serum albumin; CML,
d Plac, placebo-treated.
Table 2
RelativemRNA levels of themain collagen isoformsweremeasured in the kidney cortex of
the four groups.
Gene abbreviation Sham/Plac Sham/TETA Dia/Plac Dia/TETA
Col1a1 1.00 ± 0.21 0.93 ± 0.11 0.90 ± 0.09 1.09 ± 0.23
Col1a2 1.00 ± 0.12 0.95 ± 0.09 0.61 ± 0.07 0.64 ± 0.13⁎
Col3a1 1.00 ± 0.22 1.24 ± 0.15 0.75 ± 0.09 0.75 ± 0.34
Col4a1 1.00 ± 0.08 1.20 ± 0.13 0.82 ± 0.08 0.98 ± 0.12
Col4a4 1.00 ± 0.10 0.95 ± 0.06 0.39 ± 0.05⁎ 0.51 ± 0.07⁎
Col4a5 1.00 ± 0.06 0.81 ± 0.07 0.68 ± 0.05⁎ 0.64 ± 0.03⁎
Col6a1 1.00 ± 0.10 1.03 ± 0.12 0.62 ± 0.10⁎ 0.64 ± 0.12
Col6a2 1.00 ± 0.10 0.91 ± 0.10 0.59 ± 0.08⁎ 0.57 ± 0.09⁎
Col6a3 1.00 ± 0.08 1.36 ± 0.15 0.78 ± 0.08 0.93 ± 0.24
Values are mean ± SEM and presented as relative to the Sham/Plac group: n = 8/9
per group.
⁎ P b 0.05 vs. Sham/Plac.
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Data were analysed by two-way ANOVA followed by Tukey–Kramer
post-hoc tests (for normally-distributed data), repeated-measures
ANOVA, or the Mann–Whitney U test (for non-parametric data), as ap-
propriate. All data are shown asmean±SEM, anddifferences have been
considered signiﬁcant at P b 0.05. All between-subject variability of
measurements has been retained in all analyses: no ‘outlying’ values
were removed from any of the data sets.
3. Results
3.1. Disturbed collagen equilibrium was associated with changes in
post-translational modiﬁcation in diabetic kidneys: amelioration by
TETA treatment
STZ-injected rats became diabetic within 2 days and displayed high
blood-glucose levels throughout the remainder of the study (Fig. 1 A).
Diabetic rats had decreased body-weights starting from week 2 (Fig. 1
B). Treatment with TETA inﬂuenced neither blood-glucose levels nor
body-weight in non-diabetic or diabetic rats.
Kidney collagen extracts from healthy animals were solubilised by
pepsin treatment and qualitatively characterised by LC MS/MS analysis
of proteins separated using Coomassie blue-stained SDS-PAGE gels
(Fig. 2 A). Type I collagen was identiﬁed as the major isoform, along
with lesser amounts of collagen types III and V: these ﬁndings are
consistent with other available data [25,26].
A representative blot for the measurement of collagen-bound CML
levels from two animals per group (Fig. 2 B) and the blocking of the
BSA-AGE signal after incubation of the antibody with a CML-blocking
peptide, are shown (Fig. 2 C). CML levels were signiﬁcantly increased
in renal collagen extracts from diabetic rats (Fig. 2 D). Eight weeks'
TETA treatment decreased collagen-bound CML content to levels not
signiﬁcantly different from those in the healthy placebo-treated group.
Pepsin digestibility of collagen extracts in diabetic tissue was decreasedFig. 3. Relative LoxmRNA levels (A), LOX protein levels (B) and a representativeWestern blot (C
P b 0.05 vs. Sham/Plac. Nonstandard abbreviations: LOX, lysyl oxidase; Plac, placebo-treated.and TETA treatment was without effect in either control or diabetic tis-
sue (Fig. 2 E). Collagen levels, as determined by hydroxyproline mea-
surement, were decreased in the renal cortex of diabetic rats and
normalised by TETA treatment (Fig. 2 F). The decrease in collagen levels
in diabetes was accompanied by a trend towards decrease in mRNA
levels corresponding to all major isoforms of collagen that we detected
in kidney tissue (Table 2). This effect was signiﬁcant for four of the iso-
forms whereas TETA treatment had no effect on collagen mRNA levels.
Messenger RNA and protein levels of LOX were increased in the kidney
cortex of diabetic rats (Fig. 3 A–C).
3.2. Increased levels of collagen-degrading proteinases in kidneys of diabet-
ic rats
Mmp2mRNA levels showed a tendency towards increase in diabetic
rats whereas TETA treatment was without effect (Fig. 4 A). Kidney cor-
tex lysates were analysed for metalloproteinase activity by gelatine
zymography (Fig. 4 B) and quantiﬁed by densitometry measurement
(Fig. 4 C and D). Overall activity levels for pro-MMP2 (70 kDa) where
much higher than those of MMP-2 (60 kDa): this is likely due to the
presence of inhibitors which bind to activated MMP-2 [27]. MMP-2
activity levels displayed a tendency towards increase in the placebo-
but not the TETA-treated diabetic group (Fig. 4 C). Activity levels of
pro-MMP-2 were signiﬁcantly increased in diabetes (Fig. 4 D) whereas
a trend towards decreased MMP-2 activity levels was seen in TETA-
treated diabetic animals. Ctsl mRNA levels were increased in diabetic
renal cortices (Fig. 5 A). CTSL single-chain (CTSL sc) as well as the
processed heavy-chain of CTSL double-chain (CTSL dc) were detected
by Western blotting (Fig. 5 B) [28]. Importantly both CTSL sc and CTSL
dc display activity [29]. Levels were quantiﬁed and CTSL sc (Fig. 5
C) and CTSL dc (Fig. 5 D) were increased in diabetic renal cortices
whereas TETA treatment displayed a tendency to decrease CTSL dc
levels. CTSL activity was also slightly increased in diabetic rats (Fig. 5
E). Addition of CuCl2 in vitro decreased CTSL activity in kidney lysates
from placebo-treated healthy and diabetic rats (Fig. 5 F) whereas the
presence of TETA normalised activity in lysates from both groups.
3.3. Increased CTSL levels in the collagen-rich mesangium and interstitium
as well as tubule cells of diabetic rats and amelioration by TETA treatment
Type 1 collagen (COL1, Fig. 6 A–C) and CTSL (Fig. 6 D–F)were detect-
ed by immunoﬂuorescence staining in kidney cortices of placebo-
treated healthy, and placebo-treated and TETA-treated diabetic rats.
Nuclei were stainedwith DAPI (Fig. 6 G–I) and overlay images with im-
munoﬂuorescent staining are shown (Fig. 6 J–L). In line with the results
of quantitative collagen measurement by hydroxyproline assay, colla-
gen staining was slightly weaker in placebo-treated diabetic rats
(Fig. 6 B) compared to placebo-treated healthy rats (Fig. 6 A) while
staining in TETA-treated diabetic rats (Fig. 6 C) was slightly stronger.
CTSL in placebo-treated diabetic vs. healthy rats (Fig. 6 D vs. E) was
strongly increased. The increase was most pronounced in collagen-), are shown for renal-cortical tissue of the four treatment groups. n=18/19 per group: *,
Fig. 4.Mmp2mRNA levels in kidney cortices from the four treatment groups (n=8/9per group) are shown in (A). A representative zymographygel for kidney cortices of the four groups is
shown in (B). Quantiﬁcation of activity for the four groups (n=11/12per group) at themolecularmasses of 60 kDa forMMP-2 (C) and 72 kDa for pro-MMP-2 (D) are shown: *, P b 0.05 vs.
Sham/Plac. Nonstandard abbreviations: Mmp, matrix metalloproteinase; Plac, placebo-treated.
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the apex of tubular cells. Treatment of diabetic rats with TETA (Fig. 6
F) reversed the increase of CTSL. At higher magniﬁcation (Fig. 7 A–L)
staining of COL1 is seen to be stronger in placebo-treated healthy ani-
mals (Fig. 7 A) compared to placebo-treated diabetic animals (Fig. 7
B) with amelioration in TETA-treated diabetic animals (Fig. 7 C). Strong
staining for CTSL in placebo-treated diabetic animals compared to healthy
animals (Fig. 7 D and E) is also present. CTSL staining is pronounced in the
proximity of COL1 staining (Fig. 7 B and K) in the glomerulus aswell as in
the surrounding peritubular interstitiumwhile CTSL staining is weaker in
TETA-treated diabetic animals (Fig. 7 F).
3.4. CTSL expression correlates stronglywith extent of collagenmodiﬁcations
A strong positive correlation between CTSL sc and -dc levels and col-
lagen CML levelswas present (Fig. 8 A and B). CTSL sc and -dc levelswereFig. 5. CtslmRNA levels (A, n= 8/9 per group) and protein levels for CTSL-sc (B) and CTSL-d
representativeWestern blot (D). CTSL activity measurement (n= 11/12 per group) is shown (
and diabetic kidneys is shown relative to control (F). *, P b 0.05 vs. Sham/Plac. Nonstandard ab
placebo-treated; sc, single-chain; and TETA, triethylenetetramine.inversely correlated with pepsin digestibility (Fig. 8 C and D) in non-
diabetic and diabetic placebo treated animals. Collagen levels displayed
an inverse correlation with pro-MMP-2 (Fig. 8 E) in these animals.
4. Discussion and conclusion
The formation of AGEs in general and CML in particular is enhanced
in diabetes [3], and AGE formation impairs the digestibility of affected
proteins in vitro [4] providing a potential link with collagen accumula-
tion and ﬁbrosis [30]. Here, a decrease in the digestibility of collagen
from kidneys of diabetic animals was paralleled by elevated collagen
CML levels without collagen accumulation. On the contrary a decrease
of collagen levels was present in diabetic animals.
The diabetic state modiﬁes collagen-degrading proteinases [11,31]
whichmay alter collagen levels. Here, the collagen-degrading lysosomal
proteinase CTSL and the extracellular proteinaseMMP-2were increasedc (C) in kidney cortices of the four groups (n= 11/12 per group) are shown alongside a
E). Effect of in vitro addition of CuCl2 and TETA on CTSL activity in placebo-treated healthy
breviations: act, enzyme activity; CTSL, cathepsin L; dc, double-chain; Dia, diabetic; Plac,
Fig. 6. Immunoﬂuorescence staining of kidney cortexwith groups indicated at the top and staining on the sideof images, respectively. Sections are stainedwith type 1 collagen- (COL1) and
cathepsin L (CTSL) speciﬁc primary antibodies andAlexa Fluor 488 or Alexa Fluor 647 coupled secondary antibodies, respectively.Nuclei are stainedwithDAPI. An image overlay (Comb) of
the channels is depicted in the bottom row (scale bar = 100 μm).
1615S. Brings et al. / Biochimica et Biophysica Acta 1852 (2015) 1610–1618in diabetic animals. Activity levels of the latter correlated inversely with
collagen levels, supporting the importance of this protease for collagen
degradation. Furthermore, levels of the lysosomal proteinase CTSL,
which acts downstream of MMP-2 [9], correlated strongly with the
levels of the collagen-AGE adduct CML and inverselywith pepsin digest-
ibility of the collagen extracts. Thus, the data presented here provide the
ﬁrst in vivo evidence for a connection between a collagen-bound AGE
and a possibly adaptive dysregulation of the lysosomal proteinase CTSL.
This concept is supported by our ﬁnding that a marked increase of
CTSL is seen in the collagen-rich renalmesangiumandperitubular inter-
stitium of diabetic rats. Peres et al. has reported decreased CtslmRNA
levels 10 days after diabetes induction, whereas levels displayed a
trend for increase after 4 weeks of diabetes [13]. Thus, increased Ctsl
mRNA levels after 16 weeks of diabetes which are seen here are not in
contrast to this previous report.
The increased expression of CTSL could lead to untoward effects.
Elevated CTSL mRNA and protein levels have been reported in diabetic
nephropathy in humans [32]. Moreover, altered CTSL expression in
mice has been linked to the effacement of podocyte foot processes and
generation of proteinuria [32] and shown to drive podocyte apoptosis
and progression to end-stage renal disease [33]. Elevation of CTSL
could also exert pathogenic effects via cleavage and activation of
glomerular heparanase [34].
The in vitro proteolysis of AGE-modiﬁed substrates is impaired and
a glycation-dependent, altered degradative capacity of the cell has
been proposed as a cause of proteinuria [6]. The data presented herefor the lysosomal proteinase CTSL provide evidence for a similar
mechanism as a cause of renal ﬁbrosis in long-standing diabetes.
Lysosomes accumulate AGEs in vitro and the capacity of the lysosomal
proteolytic systemmay eventually become exhausted thus leading to ﬁ-
brosis [7]. The duration of the current study, which ran for 4 months,
may not have been long enough for ﬁbrosis to develop whereas
increased collagen levels were reported in rats following 8 months'
diabetes [35,36].
The small increase in CTSL activity as opposed to CTSL expression in
diabetic rats observed in the current study might be explained by
copper-mediated inhibition of CTSL activity. In support of this, the
in vitro addition of Cu(II) inhibited CTSL activity and was normalised
upon addition of TETA. The capacity to bind copper is increased for
peptide-boundCML residues as compared to correspondingunmodiﬁed
lysyl residues [37], and collagen-rich tendon from diabetic rats binds
twice the amount of copper as that from healthy rats [38].
The partial normalisation of CML levels by TETA treatment provides
evidence that collagen CML formation is at least partially due to
glycoxidative stress [39] and catalysed by Cu(II) ions in vivo. The ob-
served trend towards decreased CML levels rather than complete nor-
malisation could well be explained by the slow collagen turnover rate
[40,41]. TETA treatment furthermore normalised collagen levels with-
out concomitant changes in collagen mRNA, while CTSL and MMP-2
levels displayed a trend towards normalisation in TETA-treated animals.
This further supports the idea of an adaptive proteinase response in
diabetic animals.
Fig. 7. Immunoﬂuorescence staining of glomeruli (scale bar = 50 μm). Groups and staining are the same as for Fig. 6 and are indicated at the top and side of images, respectively.
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been reported after 4 days, 5 weeks [12] and 12 weeks [42] of diabetes
and by using in vitro assays in the presence of high glucose levels [43,
44]. Thus, available literature supports lower levels of MMP activity
in vitro and at time-points early after diabetes induction, while MMP-2
levels tend to be increased after mid- to long-term diabetes according
to our data. We are aware of one report of decreased MMP-2 levels,
based on immunoﬂuorescent staining of glomeruli without quantiﬁca-
tion, in a transgenic mouse model of diabetic nephropathy after
40 weeks of diabetes [45]. Differences may be due to the animal model,
namely diabetes in transgenic mice vs. STZ-induced diabetes in rats.
LOX enzymatically cross-links collagen and may thus have an effect
on the digestibility of collagen [46,47] while higher LOX levels do not
necessarily increase cross-links [48]. Here, neither LOX nor collagen
CML-levels correlated with collagen pepsin digestibility (correlation
data not shown). Thus the decrease in collagen pepsin digestibility in
diabetic animals is likely due to additive effects of a range of post-
translational modiﬁcations.
Howmight the processes identiﬁed here be responsible for the path-
ological lesions of diabetic kidney disease? Skin collagen CML levels are
a strong predictor for the risk of development of diabetic nephropathy
in humans [49]. The data presented here shed light on the molecular
basis of this association where elevated collagen CML levels and de-
creased collagen digestibility is paralleled by a possibly adaptive in-
crease of the collagen-degrading lysosomal protease CTSL in kidneys
from diabetic rats. The effects of AGEs on proteolysis can be manifoldincluding altered substrate digestibility [4] and accumulation of AGEs
in lysosomes in vitro [7]. CML in particular acts as an endogenous
Cu(II) chelator [38,50]. The inhibitory effect of Cu(II) on CTSL activity
and the ameliorative effect of TETA shown in the current study presents
an additional mechanism for an AGE-mediated altered proteolysis.
CML bound Cu(II) may contribute to the dysregulated copper ho-
meostasis seen in diabetes. Diabetic patients with chronic kidney dis-
ease show ~3–4-fold elevations in urinary copper output, consistent
with renal copper overload [51,52]. Systemic copper overload [15,53],
and elevated renal copper causes organ damage, for example in chronic
dietary copper overload [54] and diabetes [16]. TETA, a Cu(II)-selective
chelator [15,54,55–57], lowers elevated hepatic and CNS copper levels
in Wilson's disease [58], a genetic disorder of cell-copper transport
[59]. Latterly, TETA has also been applied for the experimental thera-
peutics of diabetes to treat defective copper homeostasis. TETA treat-
ment here restored collagen levels and partially normalised collagen-
CML levels and CTSL levels providing a link between an altered collagen
metabolism and dysregulated copper metabolism in diabetes.
In summary, our results provide evidence for a pathogenic mecha-
nism in kidneys of diabetic rats that acts through glycoxidative stress-
dependent modiﬁcation of collagen coupled to the dysregulation of
key proteinases, speciﬁcally CTSL and MMP-2, and consequent alter-
ations in collagen metabolism. Together, these processes may exhaust
the proteolytic potential of the cell and lead to the formation of ﬁbrosis
and glomerular basement-membrane dysfunction in the kidneys of
diabetic animals.We propose that chelation of Cu(II) by TETA represents
Fig. 8. Shown are correlation analyses of CTSL sc (A) and -dc (B) in kidney cortices vs. collagen-boundCML levels for placebo treatedhealthy- (white squares) and diabetic (white triangles)
rats. Correlation analysis of CTSL sc (C) and -dc (D) in kidney cortices vs. pepsin digestibility of kidney collagen extracts is shown for the same group of rats. The correlation
coefﬁcient r, P-value and regression line with 95% conﬁdence interval (dashed line) are shown in each graph: n = 11/12 per group.
1617S. Brings et al. / Biochimica et Biophysica Acta 1852 (2015) 1610–1618a therapeutic option to lower glycoxidative stress in diabetes that could
be incorporated as part of a therapeutic regimen in addition to glucose-
lowering treatment.
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